早产儿视网膜病变玻璃体腔注射贝伐珠单抗后的预防性周边激光与荧光素眼底血管造影
回顾性分析33例64眼接受贝伐珠单抗治疗的早产儿视网膜病变,比较经典病变与激进后部病变的再激活率及荧光素眼底血管造影表现。激进后部病变眼再激活需治疗者(8/16)多于经典病变眼(2/48,P < 0.0001),且无血管视网膜面积更大、渗漏比例更高。贝伐珠单抗治疗后预防性激光眼的结构不良结局发生率低。
要点
- 激进后部早产儿视网膜病变眼贝伐珠单抗后再激活需治疗比例高于经典病变眼(8/16 vs 2/48,P < 0.0001)。
- 平均73周经后月经龄时,激进后部病变眼无血管视网膜面积大于经典病变眼(平均4.4个视盘直径 vs 2.6个视盘直径,P = 0.0004)。
- 荧光素眼底血管造影渗漏眼比例激进后部病变眼高于经典病变眼(11/11眼 vs 22/38眼,P = 0.01)。
核心结论
- 本研究中,贝伐珠单抗治疗的激进后部早产儿视网膜病变眼较经典病变眼有更高的复发可能性和更大的持续无灌注区。
- 早产儿视网膜病变经贝伐珠单抗治疗后行预防性激光,结构不良结局发生率低。
研究设计与样本
- 回顾性病历审查,连续纳入接受贝伐珠单抗治疗的早产儿视网膜病变婴儿,随后行荧光素眼底血管造影并对持续无血管视网膜行预防性激光。
- 共纳入33例患者64眼,平均胎龄25周,平均出生体重674 g,平均随访至经后月经龄125周。
主要发现
- 初始贝伐珠单抗后需治疗的再激活在激进后部病变眼(8/16)较经典病变眼(2/48)更常见,P < 0.0001。
- 平均73周经后月经龄时,激进后部病变眼无血管视网膜面积大于经典病变眼(平均4.4个视盘直径 vs 2.6个视盘直径,P = 0.0004)。
- 荧光素眼底血管造影显示激进后部病变眼渗漏比例高于经典病变眼(11/11眼 vs 22/38眼,P = 0.01)。
- 结构不良结局发生于16只激进后部病变眼中的1只,经典病变眼无结构不良结局。
- 贝伐珠单抗后接受预防性激光的眼均无结构不良结局。
关键数值与推荐
- 再激活需治疗:激进后部病变眼8/16 vs 经典病变眼2/48(P < 0.0001)。
- 平均73周经后月经龄无血管视网膜面积:激进后部病变眼平均4.4个视盘直径 vs 经典病变眼平均2.6个视盘直径(P = 0.0004)。
- 荧光素眼底血管造影渗漏:激进后部病变眼11/11眼 vs 经典病变眼22/38眼(P = 0.01)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: To report reactivation rate after bevacizumab treatment for retinopathy of prematurity (ROP) in eyes with classic ROP (CROP) versus aggressive posterior ROP (APROP) and to report peripheral fluorescein angiography findings in these eyes. METHODS: Retrospective chart review was conducted on consecutive infants treated with bevacizumab for ROP, followed by fluorescein angiography and prophylactic laser to persistent avascular retina. RESULTS: Sixty-four eyes of 33 patients were included. Mean gestational age was 25 weeks with mean birth weight of 674 g. Mean follow-up was 125 weeks post-menstrual age (PMA). Reactivation requiring treatment after initial bevacizumab was more common in eyes with APROP (8/16) than with CROP (2/48; P < 0.0001). At mean 73 weeks PMA, eyes with APROP had more avascular retina (mean 4.4 disk diameters vs. 2.6 disk diameters; P = 0.0004) and higher percentage of leakage (11/11 eyes vs. 22/38 eyes; P = 0.01) on fluorescein angiography than in eyes with CROP. Unfavorable outcome occurred in 1 of 16 eyes with APROP and in no eyes with CROP. No eye that underwent prophylactic laser after bevacizumab had a poor structural outcome. CONCLUSION: In our study, bevacizumab-treated eyes with APROP have a higher likelihood of recurrence and larger area of persistent nonperfusion than in eyes with CROP. Treatment of ROP with bevacizumab followed by prophylactic laser has a low rate of unfavorable structural outcome.
引用
- Garcia Gonzalez JM, Snyder L, Blair M, et al. PROPHYLACTIC PERIPHERAL LASER AND FLUORESCEIN ANGIOGRAPHY AFTER BEVACIZUMAB FOR RETINOPATHY OF PREMATURITY. Retina. 2018. PMID: 28267112. doi:10.1097/IAE.0000000000001581
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。